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HIGHLIGHTS
• Many AD target combinations are being explored for multi-target drug design.
• New databases and models increase the potential of computational drug design
• Liraglutide and other antidiabetics are strong candidates for repurposing to AD.
• Donecopride a dual 5-HT/AChE inhibitor shows promise in pre-clinical studies
Alzheimer’s Disease is a complex and multifactorial disease for which the mechanism
is still not fully understood. As new insights into disease progression are discovered,
new drugs must be designed to target those aspects of the disease that cause
neuronal damage rather than just the symptoms currently addressed by single target
drugs. It is becoming possible to target several aspects of the disease pathology at
once using multi-target drugs (MTDs). Intended as an introduction for non-experts, this
review describes the key MTD design approaches, namely structure-based, in silico,
and data-mining, to evaluate what is preventing compounds progressing through the
clinic to the market. Repurposing current drugs using their off-target effects reduces
the cost of development, time to launch, and the uncertainty associated with safety
and pharmacokinetics. The most promising drugs currently being investigated for
repurposing to Alzheimer’s Disease are rasagiline, originally developed for the treatment
of Parkinson’s Disease, and liraglutide, an antidiabetic. Rational drug design can
combine pharmacophores of multiple drugs, systematically change functional groups,
and rank them by virtual screening. Hits confirmed experimentally are rationally modified
to generate an effective multi-potent lead compound. Examples from this approach
are ASS234 with properties similar to rasagiline, and donecopride, a hybrid of an
acetylcholinesterase inhibitor and a 5-HT4 receptor agonist with pro-cognitive effects.
Exploiting these interdisciplinary approaches, public-private collaborative lead factories
promise faster delivery of new drugs to the clinic.
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INTRODUCTION
Current therapies available for the treatment of Alzheimer’s
Disease (AD) show limited ability to modify the disease.
To date the focus for AD has been on the depletion of
acetylcholine, but AD is a complex multifactorial disease with
diverse clinical symptoms. AD causes the gradual onset of
multiple cognitive deficits, affecting language, episodic memory
and attention (Karran et al., 2011). The disease pathology
includes extracellular amyloid beta (Aβ) plaques, intracellular
neurofibrillary tangles, inflammation, oxidative stress, iron
dysregulation and ultimately neuronal cell death (Carreiras et al.,
2013). It is accepted that multifactorial diseases require the
simultaneous modulation of multiple targets to manage the
course of disease progression (Cavalli et al., 2008), leading to
growth in multi-target drug (MTD) design (Hopkins, 2008).
This review focuses on possible targets, their combinations, and
the three main approaches to designing MTDs: structure-based
design, data mining/repurposing, and in silico screening. The
application of rational drug design to MTDs is difficult but
with the recent advances in experimental and computational
approaches, a combined approach harnessing the best attributes
of each method should ultimately deliver success in the
future.
TARGETS AND CURRENT THERAPIES;
LIMITATIONS IN ALZHEIMER’S DISEASE
The multifactorial nature of AD means there are many possible
therapeutic targets. Current monotherapeutic treatments focus
mainly on acetylcholinesterase (AChE) inhibition due to the
early cholinergic hypothesis that cognitive dysfunctions of AD
may be attributed to decreased neurotransmission at cholinergic
synapses as a result of neuronal cell death (Bartus et al.,
1982). AChE therapies provide symptomatic relief, but fail to
reverse disease progression (Wilkinson et al., 2004; Deardorff
et al., 2015), although recent work suggests that donepezil
(Table 1) may enhance Aβ clearance (Mohamed et al., 2015).
The amyloid hypothesis that the generation of toxic Aβ from
amyloid precursor protein (APP) and Aβ aggregation result in
the pathophysiological changes associated with AD (Figure 1)
led to compounds targeting Aβ (Karran et al., 2011; Eisele
et al., 2015). Although small molecules can target Aβ aggregation
(see Table 1), the main strategy is immunotherapy, still in
clinical trials (Palmer, 2011; Wisniewski and Goñi, 2014). Better
understanding of protein aggregation is now available to guide
therapeutic intervention on both Aβ and tau aggregation (Eisele
et al., 2015).
Following on from direct targeting of Aβ, a relatively new
target in AD is the β-secretase (BACE-1) enzyme. Inhibition
of this protease BACE-1 should reduce the levels of Aβ in
the brain (Vassar, 2014). BACE-1 inhibitors in clinical trials
include AZD3293 in phase II/III (NCT02245737) and MK8931
(verubecestat) in phase III (NCT01953601). While these drugs
show promise, there are potential complications from a possible
role in synaptic function (Kandalepas and Vassar, 2014) and
increased memory impairment and seizures in BACE-1 –/– mice
(Hu et al., 2016).
Another major enzyme target, monoamine oxidase
(MAO) is inhibited in Parkinson’s Disease (PD) to spare
the neurotransmitters depleted by neuronal death. The PD drug,
rasagiline (see below), is a MAO-B inhibitor in clinical trials for
AD (Weinreb et al., 2010).
N-methyl-D-aspartate (NMDA) is a glutamate receptor and
is the only other target besides AChE for which a therapy has
been approved (Anand et al., 2014). NMDA receptors are over-
stimulated in AD brains due to excessive release of glutamate
from neurons. This causes high levels of calcium ion influx and
activation of enzymes that can cause neuronal cell death (Zheng
et al., 2014). NMDA receptors have also been linked to tau
hyper-phosphorylation and Aβ toxicity (Couratier et al., 1996).
Memantine is the only approved NMDA receptor antagonist for
the treatment of moderate to severe AD (Lipton, 2006).
Other receptors being explored are the 5-hydroxytryptamine
(5-HT) serotonin receptors, in particular subtype 4 (5-HT4R)
that is involved in mood, memory, and learning. 5-HT4R has
been linked to memory deficits such as those seen in AD (Cho
and Hu, 2007; Lezoualc’h, 2007; Russo et al., 2009). Stimulation
causes release of ACh and increases other neurotransmitters
(Licht et al., 2010).
Inhibition of these targets individually with current drugs
(Table 1) has been ineffective at reversing the progression of the
disease. A possible answer lies in a polypharmacological approach
to modify activities of several of these targets simultaneously,
particularly those associated with the progression of the
disease. MTDs developed for AD have modified two or
more of known targets (cholinesterases, MAOs, acetylcholine
receptors, serotonin receptors) or have properties thought to
retard disease progression, such as metal chelation, antioxidant
or anti-inflammatory activity, or prevention of Aβ or tau
aggregation. Ligands for combinations of drug targets should
be evaluated against disease progression to define optimal target
combinations.
DATAMINING AND REPURPOSING
Repurposing is the development of existing or abandoned drugs
for new indications (Boguski et al., 2009), related to the original
purpose or after off-target effects are identified by datamining.
Repurposing reduces the time to launch, cost of development,
and the uncertainty associated with safety and pharmacokinetics
(Kim, 2015).
Datamining is a way of using pre-existing knowledge about
molecules and applying it to develop new drugs (Sirota et al.,
2011; Corbett et al., 2012, 2013). For example, clinical data can
be used to identify unanticipated benefits in side effects seen
in clinical trials, allowing the early repurposing of therapies
(Loging et al., 2011). The most promising drug currently being
investigated for repurposing is rasagiline, a selective, irreversible
MAO-B inhibitor for the treatment of PD (Youdim et al.,
1995, 2001). The repurposing to AD stems from the ability
of rasagiline to regulate the non-amyloidogenic processing of
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TABLE 1 | Targets, drugs, and new multi-target ligands to combat Alzheimer’s Disease (AD).
Targets Drug name Structure Comment
(A) APPROVED DRUGS
Acetylcholinesterase Donepezil Approved drug
Rivastigmine Approved drug
Galantamine Approved drug
Tacrine Withdrawn
Monoamine oxidase Rasagiline Approved for PD
Phase II for AD
Targets Parent compounds Compound References
(B) MULTI-TARGET DESIGNED LIGANDS
Cholinesterase
Aβ aggregation
Oxoisoaporphine
Tacrine
Tang et al., 2011
Cholinesterase
Aβ aggregation
Donepezil Ozer et al., 2013
AChE
BACE-1
Huprine
Tacrine
H
N
H
N
8
N
Cl
Galdeano et al., 2012
(Continued)
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TABLE 1 | Continued
Targets Parent compounds Compound References
Cholinesterase
MAO
Aβ aggregation
Donepezil
Compound 28 (Pérez et al.,
1999)
N
N N N
CN
Samadi et al., 2012
Cholinesterase
MAO
Donepezil
Compound 28
N
O
N
H
N
Compound 2
Bolea et al., 2011
MAO
Cholinesterase
Donepezil
PF9601N
N
O
N
HN
Bautista-Aguilera et al.,
2014b
MAO
Cholinesterase
Tacrine
Selegiline (deprenyl)
N
H
N O9
N
selegiline
Lu et al., 2013b
Cholinesterase
Reactive oxygen species
Memoquin
Lipoic acid
N N
H
O O
S S
lipoic acid Rosini et al., 2011
MAO
Metal chelator
Aβ aggregation
Cholinesterase
Resveratrol
HO
H
N
HO
N
Lu et al., 2013a
Metal chelator
Aβ aggregation
Resveratrol
Clioquinol
N
HO
OH
OH
Li et al., 2014
APP (Yogev-Falach et al., 2003; Bar-Am et al., 2004). Rasagiline
also shows neuroprotective activity due to the propargylamine
moiety that activates Bcl-2 and down-regulates the Bax proteins
(Youdim et al., 2005). It is now in Phase II trial for the treatment
of AD (www.clinicaltrials.gov/ct2/show/NCT02359552).
Natural products provide another potential source of MTDs
(Ji et al., 2009; Prati et al., 2014). Datamining could harness their
potential and then synthetic analogs and derivatives created to
enhance their activity (Agis-Torres et al., 2014). Huperzine A, a
dietary supplement in China, is an AChE inhibitor (Xing et al.,
2014) seemingly with beneficial effects on cognitive function and
daily living in AD patients, but the clinical trials to date have poor
methodological approaches and so results are inconclusive (Xu
et al., 1995; Rafii et al., 2011). Synthetic derivatives like huprine X
and huprine-tacrine hybrids have been developed to improve on
the potency and efficacy of huperzine A (Galdeano et al., 2012).
One promising repurposing area is from diabetes to AD,
first considered because type 2 diabetes is a risk factor for
AD (Schrijvers et al., 2010). Insulin signaling is impaired in
the brains of Alzheimer’s patients (Moloney et al., 2010) so
several aspects of insulin signaling and regulation have been
targeted. For example, Phase II clinical trials of intranasal
insulin administration showed improved biomarkers for early
AD including amyloid and tau indicators in cerebrospinal
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FIGURE 1 | Schematic of the amyloid hypothesis, the targets associated with AD, and potential drug intervention strategies. Red, disease outcomes;
Orange, Pathology; Green, Intervention strategies and drug classes.
fluid (CSF) (Craft et al., 2012). Long-lasting glucagon-like
peptide 1 (GLP-1) analogs that promote the secretion of
insulin are also in clinical trials. Three GLP-1 analogs with
potential therapeutic value in AD (Corbett et al., 2012; Hölscher,
2014), have shown in vivo benefits in mouse AD models
(Gengler et al., 2012). Two of these are Exendin-4 in Phase II
clinical trial (See www.clinicaltrials.gov/ct/show/NCT01255163)
and Liraglutide, a GLP-1 receptor agonist. Liraglutide crosses
the blood brain barrier (BBB) in animal models (Hunter and
Hölscher, 2012). It decreases intracellular APP, Aβ, and Fe2+-
related neurodegeneration, but also improves synaptic plasticity
and cognitive function, reducing AD pathology (McClean et al.,
2011; McClean and Hölscher, 2014).
DATABASES AND OPEN-ACCESS MINING
The construction of AD knowledge bases will facilitate
the repurposing of drugs and our understanding of the
neurosignaling pathways involved. One such example
is AlzPlatform, an AD domain-specific chemogenomics
database allowing the identification of off-target effects and
the repurposing of compounds (Liu et al., 2014). AlzPlatform
contains the established computational algorithm TargetHunter,
which is an in silico target identification tool for small molecules
(Wang et al., 2013).
While there is a wealth of open access chemical information
available to aid repurposing of FDA approved drugs, compound
libraries held by pharmaceutical companies are, for the most
part, unavailable. Datamining to find possible targets for
these compounds could prove fruitful. An open-innovation
drug-repositioning project between AstraZeneca and the
Medical Research Council (http://www.labtalk.astrazeneca.
com/hot-topics/open-innovation-in-drug-repositioning/) has
started and the National Center for Advancing Translational
Sciences (NCATS) has created a similar collaboration with
8 pharmaceutical companies. One of the compounds from
this program is the Src tyrosine kinase inhibitor, AZD0530
(Saracatinib), being repurposed for the treatment of AD
(Larson et al., 2012; Nygaard et al., 2014). The European Lead
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Factory (www.europeanleadfactory.eu) is another initiative
set up to allow sharing of commercial compound libraries
via collaborative public-private partnerships. The compound
library, a pool of 30 partner libraries, provides a collection of
over 500,000 compounds available for academic groups and
pharmaceutical companies to screen experimentally against
their chosen targets with great potential to generate new
therapeutics.
RATIONAL DRUG DESIGN
Rational drug design is a traditional method for drug
development based on structure-function analysis. Successful
rational drug design requires the logical and systematic changing
of substituents to modify the properties of a compound to
reach the desired effect. When applied to MTD design, it means
combining pharmacophores of multiple drugs to give complex
combinations, then compensating for any disadvantage to the
individual targets.
M30, a brain-permeable iron chelator and brain selective
MAO inhibitor, was designed on the rationale that MAO and
iron are elevated in the brains of AD patients, and this leads
to oxidative stress and neurodegeneration (Youdim, 2006). The
MAO inhibition is due to the propargylamine of the FDA-
approved anti-PD drug rasagiline (Youdim, 2013). The iron
chelating activity comes from the prototype iron chelator VK28
(Zheng et al., 2014). M30 irreversibly inhibits both MAO-A and
-B with IC50 values of 37 ± 2 nM and 57 ± 1 nM respectively,
less selective than rasagiline (412 nM and 4.4 nM, respectively)
(Zheng et al., 2005). It also regulates APP via its iron chelating
ability since APP is a metalloprotein with an iron responsive
element in the 5′ untranslated region (UTR) (Youdim, 2013).
Therefore, it has a direct effect on Aβ levels.
To reduce the possibility of adverse effects of metal chelation
in the periphery, a second-generation molecule and prodrug,
M30D, was designed from tacrine, rivastigmine, and rasagiline
(Zheng et al., 2010a,b, 2014). It was 3-fold more potent against
MAO-A (IC50 of 7.7 nM) than the parental molecule, retaining
the sameMAO-B inhibition (Zheng et al., 2014). It is metabolized
to the active chelator form M30 by AChE and inhibits AChE
with an IC50 of 500 nM in rat brain homogenates. With these
characteristics, M30D is the first site-directed metal chelator with
the potential to treat AD.
A similar MTD is ASS234 composed from donepezil and
the propargylamine PF9601N. It binds to all the AChE/BuChE
and MAO A/B enzymes, shows antioxidant, neuroprotective
and suitable permeability properties. In vivo, ASS234 restores
scopolamine-induced cognitive impairment to the same extent as
donepezil, is less toxic, and prevents β-amyloid aggregation in the
cortex of AD transgenic mice (Bolea et al., 2013; del Pino et al.,
2014).
Another promising structure-based MTD is donecopride.
Donecopride is a structural hybrid of donepezil, an AChE
inhibitor, and RS67333, a 5-HT4R agonist. RS67333 is a partial
5-HT4R agonist that exerts a procognitive effect via its ability
to promote cleavage of APP. RS67333 is structurally similar
to donepezil, so it was postulated that it might inhibit AChE.
It was indeed a submicromolar AChE inhibitor (Lecoutey
et al., 2014; Rochais et al., 2015). Derivatives of RS67333 were
then synthesized to improve the AChE activity, from which
MR31147 (donecopride) was selected for its remarkable multi-
target activity in vitro, including an IC50 for AChE of 16 nM
(Lecoutey et al., 2014). Donecopride crosses BBB, has a nontoxic
profile, and exerts a procognitive effect in vivo (Lecoutey
et al., 2014). It will be interesting to see how this promising
molecule progresses since 5-HT4 targeted therapies have been
less commonly explored for AD.
These examples show how methodical rational drug design
and experimental screening can be used to generate promising
MTD candidates for the treatment of AD.
IN SILICO SCREENING
Rational drug design is currently the approach of choice for
MTD design but it is labor intensive, so there is a need for more
in silico screening to reduce costs and accelerate progress. New
computer-based approaches for in silico screening (Ekins et al.,
2007a; Wang et al., 2013), such as quantitative structure-activity
relationships, molecularmodeling approaches, machine learning,
data mining, and data analysis tools, use in vitro data to generate
predictive models. Such models are very useful in the discovery
and optimization of novel ligands with enhanced affinity to a
drug target, as well as for optimization of physicochemical and
pharmacokinetic properties of the drug candidates. Several of
these in silico methods will be evaluated here in the context of
selected MTD examples.
Virtual ligand screening is an alternative to experimental high
throughput screening (Ekins et al., 2007a). It can be used to
screen whole databases of molecules and rank them based on
their probability of binding to a drug target. The highest-ranking
molecules can then be taken through to an experimental stage to
confirm the hits and determine the most promising leads. Virtual
screening can be either ligand based, where a diverse set of ligands
are analyzed to build up a pharmacophore to score the screen
against, or it can be structure-based, where molecules are docked
onto the target and scored based on their likely affinity for the
target. Quantitative structure-activity relationships (QSAR) is a
form of ligand-based virtual screening but it uses a series of logic-
based rules describing the chemical properties and substructures
linked to activity to screen a database of molecules (Ekins et al.,
2007b).
Recently a virtual ligand screen (Bautista-Aguilera et al.,
2014a) was used for lead optimization of two donepezil hybrid
compounds shown previously to inhibit MAO-A, MAO-B,
AChE, and BuChE (Bolea et al., 2011). The 3D-QSAR analysis
was carried out both to explain the binding of these compounds
to the active sites of the enzymes and to predict substitutions
that would increase binding. The QSAR model was used to
generate 19 new molecules with substitutions predicted to
increase the activity against MAOs and ChEs. The predicted IC50
values suggested that N-[(5-benzyloxy-1-methyl-1-H-indol-2-
yl)methyl]-N-methylprop-2-yn-1-amine (compound 2) would
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be themost potent inhibitor of all four enzymes with values in the
nanomolar range for MAO-A, MAO-B, and AChE, while BuChE
was predicted at 1.3µM. The experimental results showed that
only 7 of the 19 compounds were active against all four enzymes,
which demonstrates how difficult it can be to get activity against
four enzymes in one molecule. However, as predicted, compound
2 was the most potent against all four enzymes, confirming
the quality of the 3D-pharmacophores. Thus, in silico screening
can be used to modify a lead compound and generate effective
multi-potent inhibitors (Bautista-Aguilera et al., 2014a).
Another option, rather than start from a lead molecule, is
to use pharmacophore models to screen existing compound
databases with the aim of generating hits against multiple targets.
This approach has been used to identify dual inhibitors of
BACE-1 and AChE using a combination of virtual screening
and molecular docking of compounds from three compound
databases. The strategy adopted follows a sequential screening
model where the databases were screened in parallel against the
two targets sequentially before filters were applied to select for
compounds with desirable properties. Finally, docking of the
chosen compounds led to 8 compounds from the original 501,799
that fit all the given criteria (Tyagi et al., 2010).
Importantly, in silico screening allows the early filtering of
compounds based on properties, such as BBB permeability, which
can reduce late stage attrition. However, screening sequentially
means that compounds that fall below the cut-off criteria in
the first round are not screened against the second target. To
avoid loss of potential candidates, screening against the targets
in parallel is essential (Steindl et al., 2006).
CONCLUDING REMARKS
Over the past decade, there has been a substantial research
effort to design MTDs for the treatment of AD. This focus on
MTDs is aided by the understanding that AD is a complex
andmultifactorial disease affectingmany interlinked pathological
pathways. The lack of efficacy seen with the single target approach
is compelling evidence that we needed to rethink the paradigm
of drug design to treat these multifactorial diseases. MTD design
offers a promising avenue for the progression of AD therapeutic
intervention and could ultimately lead to a drug with the ability
to reverse disease progression.
While there are many targets for disease-modifying drugs, it
remains to be seen which combinations will prove efficacious.
It seems logical that in order to reverse disease progression,
we must target those aspects of the disease that cause neuronal
damage, such as Aβ and oxidative damage, rather than just
targeting the breakdown enzymes to alleviate the deficiencies
caused by cell death. Of course, targeting a combination of both
would relieve symptoms and prevent further neuronal loss.
In terms of the approach to MTD design, an integrated
approach using a combination of in silico and rational drug
design should reduce the cost of high throughput screening
and progress discovery more rapidly. The MTD approach is
also being used to combat the development of resistance to
antimicrobials. MBX-500 has been designed as a hybrid of
two classes of antibiotics, fluoroquinolone and anilinouracil,
for the treatment of Clostridium difficile infections (Butler
et al., 2012). TD-1792, a cephalosporin-vancomycin hybrid, has
passed a phase II clinical trial for gram-positive skin infections
(Stryjewski et al., 2012). While MTD design is in its infancy in
the world of antibiotics, there is evidence that it could prove
promising here too (East and Silver, 2013; Oldfield and Feng,
2014).
Overall, MTD design is a promising approach to modern
medicines for complex diseases. Whether drugs will come from
repurposing, rational drug design, in silico screening, or a
combination approach we cannot predict, but the race is on
to develop the first approved MTD capable of reversing AD
pathology.
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